Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2017 |
Outros Autores: | , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10451/35015 |
Resumo: | Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. |
id |
RCAP_60001638ca310c40f6a55690b05407f2 |
---|---|
oai_identifier_str |
oai:repositorio.ul.pt:10451/35015 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe?Hematological diseasesImatinib mesylateProtein-tyrosine kinase inhibitorCardiotoxicityNilotinibPublished on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017.Introduction: Chemotherapy-induced cardiotoxicity is a growing concern. The true cardiotoxic impact of new drugs such as tyrosine kinase inhibitors is unknown, especially the ones used for chronic myeloid leukaemia. We aim to evaluate nilotinib and imatinib induced cardiotoxicity. Methods: Single-center prospective study of consecutive patients with chronic myeloid leukaemia treated with tyrosine kinase inhibitors during 2015. Patients underwent an initial clinical, laboratorial and echocardiographic evaluation, repeated one year after therapy initiation. Results: Eleven patients were included [60.0 (11) years, 63.6% of males; 7 patients treated with imatinib and 4 with nilotinib]. After one year of follow-up, all patients remained in functional NYHA class I, with a similar Minnesota quality of life score [21 (20) vs. 21 (19), p = NS]. Also there was no difference in the biomarkers evaluated: cystatin-C [0.9 (0.2) vs. 0.8 (0.2) mg/L, p = NS; NT-proBNP 46.0 (45.0) vs. 42.0 (34.0) pg/mL, p = NS]. Previous to the TKI treatment, all patients had normal left ventricular ejection fraction (LVEF) [(median 67% (63–69)], without structural abnormalities. During the follow-up, there weren't differences regarding the LVEF, left atrium volume, E/A ratio, deceleration time, septal e', lateral e', E/e' ratio and tricuspid annular plane systolic excursion. With regard to myocardial deformation, all patients presented normal values of longitudinal, circumferential and radial strain in the baseline study, without changes during follow-up [DML -21.3 (6, 1) vs. -21.7 (6.0)%, p = NS; DMC -20.0 (9.3) vs. -22.3 (5.3)%, p = NS; DMR 36.9 (21.3) vs. 39.2 (19.2)%, p = NS]. In addition, there were no differences between the two tyrosine kinase inhibitors used, considering all the aforementioned variables. Conclusion: No clinical, laboratory or echocardiographic evidence of nilotinib and imatinib induced cardiotoxicity was observed, even when myocardial deformation analysis was performed. However, these results should be confirmed in larger studies, ideally multicentre, given the low incidence of chronic myeloid leukaemia.Oxford University PressRepositório da Universidade de LisboaFrancisco, A. R. Gaspar LopesAlves, D.Gonçalves, I. S.Menezes, M. N.Silva, G. Lima daGuimarães, T.David, C.Braga, J.Guerra, L.Pinto, Fausto J.Almeida, A. G.2018-10-12T10:58:23Z20172017-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/35015engEuropean Heart Journal, Volume 38, Issue suppl_10195-668X10.1093/eurheartj/ehx493.P6161info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:30:40Zoai:repositorio.ul.pt:10451/35015Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:49:35.109581Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? |
title |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? |
spellingShingle |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? Francisco, A. R. Gaspar Lopes Hematological diseases Imatinib mesylate Protein-tyrosine kinase inhibitor Cardiotoxicity Nilotinib |
title_short |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? |
title_full |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? |
title_fullStr |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? |
title_full_unstemmed |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? |
title_sort |
Cardiotoxicity in haematological diseases : are the tyrosine kinase inhibitors imatinib and nilotinib safe? |
author |
Francisco, A. R. Gaspar Lopes |
author_facet |
Francisco, A. R. Gaspar Lopes Alves, D. Gonçalves, I. S. Menezes, M. N. Silva, G. Lima da Guimarães, T. David, C. Braga, J. Guerra, L. Pinto, Fausto J. Almeida, A. G. |
author_role |
author |
author2 |
Alves, D. Gonçalves, I. S. Menezes, M. N. Silva, G. Lima da Guimarães, T. David, C. Braga, J. Guerra, L. Pinto, Fausto J. Almeida, A. G. |
author2_role |
author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
dc.contributor.author.fl_str_mv |
Francisco, A. R. Gaspar Lopes Alves, D. Gonçalves, I. S. Menezes, M. N. Silva, G. Lima da Guimarães, T. David, C. Braga, J. Guerra, L. Pinto, Fausto J. Almeida, A. G. |
dc.subject.por.fl_str_mv |
Hematological diseases Imatinib mesylate Protein-tyrosine kinase inhibitor Cardiotoxicity Nilotinib |
topic |
Hematological diseases Imatinib mesylate Protein-tyrosine kinase inhibitor Cardiotoxicity Nilotinib |
description |
Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. |
publishDate |
2017 |
dc.date.none.fl_str_mv |
2017 2017-01-01T00:00:00Z 2018-10-12T10:58:23Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/35015 |
url |
http://hdl.handle.net/10451/35015 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
European Heart Journal, Volume 38, Issue suppl_1 0195-668X 10.1093/eurheartj/ehx493.P6161 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Oxford University Press |
publisher.none.fl_str_mv |
Oxford University Press |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799134428621963264 |